Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Open-label, Multi-center, Phase I/II Study Evaluating the Safety and Clinical Activity of QEL-001, an Autologous CAR T Regulatory Cell Treatment Targeting HLA-A2, in HLA-A2/ A28neg Patients That Have Received an HLA-A2pos Liver Transplant

Next Previous
Trial Profile

A Single-arm, Open-label, Multi-center, Phase I/II Study Evaluating the Safety and Clinical Activity of QEL-001, an Autologous CAR T Regulatory Cell Treatment Targeting HLA-A2, in HLA-A2/ A28neg Patients That Have Received an HLA-A2pos Liver Transplant

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QEL-001 (Primary)
  • Indications Liver transplant rejection
  • Focus Adverse reactions; First in man
  • Acronyms LIBERATE
  • Sponsors Quell Therapeutics

Most Recent Events

  • 10 Jun 2025 According to Quell Therapeutics media release, the company is looking forward to sharing first efficacy data from the LIBERATE Phase 1b/2 trial later this year.
  • 22 Oct 2024 According to a Quell Therapeutics media release, company announces upcoming poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, held in San Diego, CA November 16.
  • 22 Oct 2024 According to a Quell Therapeutics media release,company announces upcoming oral presentation at the 2024 European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress, held in Rome, Italy October 24.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top